Home
PTGX
PTGX News

Latest Protagonist Therapeutics Inc. (PTGX) News on December 22, 2024

ACCESSWIRE

3 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

Argus Research

5 days ago

PTGX: Lowering target price to $43.00

Argus Research

12 days ago

PTGX: Raising target price to $44.00

ACCESSWIRE

13 days ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

MT Newswires

16 days ago

Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

TipRanks

16 days ago

Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities

Argus Research

19 days ago

PTGX: Lowering target price to $43.00

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

23 days ago

Is Weakness In Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Argus Research

23 days ago

Daily – Vickers Top Buyers & Sellers for 11/29/2024

MT Newswires

23 days ago

Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing

MT Newswires

23 days ago

Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing

MT Newswires

23 days ago

Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing

Argus Research

a month ago

PTGX: Raising target price to $47.00

ACCESSWIRE

a month ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

ACCESSWIRE

a month ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

a month ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

ACCESSWIRE

a month ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Zacks

a month ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know

Argus Research

a month ago

PTGX: Lowering target price to $45.00

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a month ago

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

a month ago

Protagonist Therapeutics: Q3 Earnings Snapshot

ACCESSWIRE

a month ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Argus Research

2 months ago

PTGX: Lowering target price to $48.00

ACCESSWIRE

2 months ago

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

MT Newswires

2 months ago

Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target

ACCESSWIRE

2 months ago

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

Insider Monkey

2 months ago

Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

GuruFocus.com

2 months ago

State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc

Argus Research

2 months ago

PTGX: Lowering target price to $46.00

MT Newswires

3 months ago

TD Cowen Initiates Protagonist Therapeutics at Buy

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Benzinga

3 months ago

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines

Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years

Simply Wall St.

3 months ago

Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years

ACCESSWIRE

4 months ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Argus Research

4 months ago

PTGX: What does Argus have to say about PTGX?

Argus Research

4 months ago

PTGX: Raising target price to $44.00

MT Newswires

5 months ago

Protagonist Therapeutics Shares Fall After Q2 Revenue Miss

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates

Zacks

5 months ago

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

5 months ago

Protagonist Therapeutics: Q2 Earnings Snapshot

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ACCESSWIRE

5 months ago

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

ACCESSWIRE

5 months ago

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

ACCESSWIRE

5 months ago

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

ACCESSWIRE

5 months ago

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

MT Newswires

5 months ago

JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating

MT Newswires

5 months ago

BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating

Argus Research

5 months ago

PTGX: What does Argus have to say about PTGX?

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

ACCESSWIRE

5 months ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

5 months ago

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Argus Research

5 months ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Investor's Business Daily

6 months ago

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Associated Press

6 months ago

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

MT Newswires

6 months ago

Protagonist Therapeutics to Join S&P SmallCap 600

Protagonist Therapeutics Set to Join S&P SmallCap 600

PR Newswire

6 months ago

Protagonist Therapeutics Set to Join S&P SmallCap 600

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

Insider Monkey

6 months ago

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Simply Wall St.

6 months ago

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

ACCESSWIRE

6 months ago

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

MT Newswires

6 months ago

Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing

MT Newswires

6 months ago

Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing

Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Simply Wall St.

6 months ago

Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

ACCESSWIRE

7 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

ACCESSWIRE

7 months ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations

GuruFocus.com

7 months ago

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations

Associated Press Finance

7 months ago

Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

ACCESSWIRE

7 months ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

ACCESSWIRE

7 months ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Simply Wall St.

8 months ago

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Turnstone Biologics Appoints William Waddill to its Board of Directors

GlobeNewswire

8 months ago

Turnstone Biologics Appoints William Waddill to its Board of Directors

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

Zacks

9 months ago

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

GuruFocus.com

9 months ago

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%

Simply Wall St.

9 months ago

Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

ACCESSWIRE

9 months ago

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet

Zacks

9 months ago

Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

ACCESSWIRE

9 months ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

ACCESSWIRE

9 months ago

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

ACCESSWIRE

10 months ago

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

Zacks

10 months ago

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Simply Wall St.

10 months ago

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.

10 months ago

Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?

Zacks

10 months ago

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

10 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade

Zacks

10 months ago

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade

Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why

Zacks

10 months ago

Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why

Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

10 months ago

Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations

We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn

Simply Wall St.

10 months ago

We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn

Associated Press Finance

10 months ago

Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ACCESSWIRE

10 months ago

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

ACCESSWIRE

10 months ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Protagonist Therapeutics Reports Granting of Inducement Awards

ACCESSWIRE

10 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

GuruFocus.com

10 months ago

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

ACCESSWIRE

10 months ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Zacks

a year ago

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Exxon, Chevron show production strength despite sector woes

Yahoo Finance Video

a year ago

Exxon, Chevron show production strength despite sector woes

SkyWest Inc (SKYW) Reports Q4 and Full-Year 2023 Earnings, Reveals Increased Revenue and Net Income

GuruFocus.com

a year ago

SkyWest Inc (SKYW) Reports Q4 and Full-Year 2023 Earnings, Reveals Increased Revenue and Net Income

Takeda pays $300M to license Protagonist drug for blood disorder

BioPharma Dive

a year ago

Takeda pays $300M to license Protagonist drug for blood disorder

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

ACCESSWIRE

a year ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

12 Stocks with Potential to Explode

Insider Monkey

a year ago

12 Stocks with Potential to Explode

Customers Bancorp, Inc. Declares Quarterly Cash Dividend on Its Series E and Series F Preferred Stock

Business Wire

a year ago

Customers Bancorp, Inc. Declares Quarterly Cash Dividend on Its Series E and Series F Preferred Stock

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

ACCESSWIRE

a year ago

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

GuruFocus.com

a year ago

Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

Delek US Holdings to Host Fourth Quarter 2023 Conference Call on February 27th

PR Newswire

a year ago

Delek US Holdings to Host Fourth Quarter 2023 Conference Call on February 27th

Share on Social Networks: